ArticleClinical rheumatology2026
Kawasaki disease in adolescents: age-specific clinical features and factors associated with outcomes.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn adolescents, Kawasaki disease (KD) often manifests with non-specific clinical symptoms, which delays diagnosis and treatment and consequently increases the risk of coronary artery lesions (CALs). This study investigated the clinical characteristics of KD across age groups, focusing on adolescents, and identified age-specific factors associated with treatment resistance and CALs.
methodsA retrospective analysis was conducted using nationwide survey data compiled in South Korea from 2009 to 2017.
resultsA total of 34,408 patients with KD were stratified into four age groups at the time of diagnosis: < 1 year (7425; 21.6%), 1-4 years (22,629; 65.8%), 5-9 years (4089; 11.9%), and ≥ 10 years (265; 0.8%). Compared to younger age groups, the ≥ 10-year age group had a greater proportion of males, longer total and pre-admission fever duration, a greater likelihood of incomplete KD with fewer typical symptoms, more cervical lymphadenopathy, and less erythema at the Bacillus Calmette-Guérin inoculation site. Although some differences were not statistically significant, this group had higher rates of unresponsiveness to first and second intravenous immunoglobulin (IVIG) treatments and second-line steroid use, and more coronary dilatation and aneurysms, but no differences in coronary stenosis, occlusion, or mortality. In adolescents, IVIG unresponsiveness was only associated with prolonged fever, and CALs was associated with recurrent KD, prolonged fever, lower total protein levels, and fewer acute-phase extremity changes.
conclusionsAdolescents with KD exhibit distinct clinical features, characteristic age-specific risk factors, and a higher risk of CALs, highlighting the need for age-specific management strategies. Key Points • KD in adolescence is rare, accounting for approximately 0.8% of all cases. • Adolescents with KD exhibited longer fever duration, more incomplete KD presentation, higher rates of unresponsiveness to IVIG, and a greater incidence of CALs. • Prolonged fever and recurrent KD were associated with treatment resistance and CALs in adolescent KD.
Indexed as
Identifiers
41557166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.